查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1612200

抗菌药物抗药性监测市场：按组件、最终用户划分 - 2025-2030 年全球预测

Antimicrobial Resistance Surveillance Market by Component (Diagnostic Kits, Diagnostic Systems, Services), End-User (Hospitals, Research & Academic Institutes) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗菌药物抗药性监测市场价值为56亿美元，预计到2024年将达到59.6亿美元，复合年增长率为6.49%，预计到2030年将达到87.1亿美元。

抗菌素抗药性 (AMR) 监测是指系统收集、分析和解释与病原体中抗菌素抗药性的盛行率和模式相关的资料。需要这项重要的公共卫生工具来监测抗药性如何传播，指导抗生素的使用，并为新药和治疗通讯协定的开发提供资讯。抗菌素抗药性监测适用于整个医疗机构、社区环境和国家卫生系统，最终用户包括医院、诊断实验室、研究机构、製药公司和政府机构。该领域的市场成长受到以下因素的推动：抗药性感染疾病的日益流行、由于有效选择耗尽而对新型抗生素的迫切需求，以及政府的支持性政策以及全球强调协调一致的抗微生物药物抗药性策略的努力。快速诊断测试等技术进步以及公共和私营部门研发资金的增加带来了巨大的机会。此外，人工智慧和巨量资料分析提供了创新和先进调查方法的潜力。然而，这个市场面临着挑战​​，例如与新诊断技术相关的高成本以及资源匮乏地区的专业知识有限，这些都是采用的障碍。此外，由于国家标准和监测能力不同而导致资料不一致，使全球努力变得复杂。为了实现业务成长，创新应专注于提高快速诊断的成本效益和可及性、利用人工智慧进行预测建模以及扩大即时检测。与国际卫生组织的持续合作也提供了策略优势。市场动态是动态的，反映了对解决方案的迫切需求，相关人员优先考虑适应、跨境合作和创新技术的整合，以克服快速发展的微生物威胁。

主要市场统计
基准年[2023] 56亿美元
预计年份 [2024] 59.6亿美元
预测年份 [2030] 87.1亿美元
复合年增长率（%） 6.49%

市场动态：快速发展的抗菌药物抗药性监测市场的关键市场洞察

供需的动态交互作用正在改变抗菌药物抗药性监测市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 病原体引起的感染疾病增加
    • 政府采取更多措施来提高诊断和照护现场诊断的质量
  • 市场限制因素
    • 与抗菌药物抗药性监测相关的高成本
  • 市场机会
    • 对管理抗菌素抗药性 (AMR) 感染的先进诊断解决方案的需求不断增长
    • 全球诊断药物核准量增加
  • 市场挑战
    • 缺乏抗菌素抗药性监测的标准化方法和指南

波特的五力：驾驭抗菌药物抗药性监测市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗菌药物抗药性监测市场的外部影响

外部宏观环境因素在塑造抗菌素抗药性监测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗菌药物抗药性监测市场的竞争格局

抗菌素抗药性监测市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵抗菌药物抗药性监测市场供应商的绩效评估

FPNV 定位矩阵是评估抗菌药物抗药性监测市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为抗菌药物抗药性监测市场的成功指明道路

对于旨在加强其在全球市场的影响力的公司来说，抗菌素抗药性监测市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 病原体引起的感染疾病传播增加
      • 政府加大力度提高诊断和照护现场诊断的质量
    • 抑制因素
      • 与抗菌药物抗药性监测相关的高成本
    • 机会
      • 对管理抗菌素抗药性 (AMR)感染疾病的先进诊断解决方案的需求不断增长
      • 全球诊断产品的监管核准数量增加
    • 任务
      • 缺乏抗菌素抗药性监测的标准化方法和指南
  • 市场区隔分析
    • 组件：诊断试剂套件在以相对较低的成本快速检测特异性抗性标记物方面发挥重要作用
    • 最终用户：医院感染发生率的增加推动了对下一代抗菌素抗药性 (AMR) 监测的需求。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章抗菌药物抗药性监测市场：依组成部分

  • 诊断套件
  • 诊断系统
  • 服务
  • 软体

第七章 抗菌药物抗药性监测市场：依最终用户分类

  • 医院
  • 研究/学术机构

第八章美洲抗菌药物抗药性监测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区抗菌药物抗药性监测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲抗菌药物抗药性监测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • AI 驱动的 AMRx 工具用于先进的抗菌药物抗药性诊断和治疗，提高准确性和患者治疗效果
    • Visbee Medical 获得 180 万美元资金，用于推进具有抗生素抗药性筛检功能的可携式淋病检测
    • Novo Holdings 收购 Paratech Pharmaceuticals 以加强对抗抗药性感染疾病的斗争
    • AMR行动基金扩大对抗抗生素抗药性的投资
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • acquired by bioMerieux SA
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bruker Corporation
  • Cepheid by Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Hologic, Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services Inc.
  • Liofilchem Srl
  • Luminex Corporation by DiaSorin SpA
  • Merck & Co., Inc.
  • Novo Holdings A/S
  • OpGen, Inc.
  • Pfizer Inc.
  • QIAGEN GmbH
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Venatorx Pharmaceuticals, Inc.
  • Viatris Inc.
  • Vivli Inc.
  • Wolters Kluwer NV
Product Code: MRR-CF6C60CF95A8

The Antimicrobial Resistance Surveillance Market was valued at USD 5.60 billion in 2023, expected to reach USD 5.96 billion in 2024, and is projected to grow at a CAGR of 6.49%, to USD 8.71 billion by 2030.

Antimicrobial resistance (AMR) surveillance refers to the systematic collection, analysis, and interpretation of data related to the prevalence and patterns of antimicrobial resistance in pathogens. This critical public health tool is necessary to monitor how resistance is spreading, to guide the use of antimicrobial agents, and to inform on the development of new drugs and treatment protocols. AMR surveillance is applied within healthcare facilities, community settings, and through national health systems, with an end-user scope that includes hospitals, diagnostic labs, research institutes, pharmaceutical companies, and governmental bodies. Market growth in this field is influenced by the increasing prevalence of drug-resistant infections, the urgent need for novel antimicrobials due to the depletion of effective options, and supportive government policies alongside global initiatives that emphasize collaborative strategies against AMR. Technological advancements, like rapid diagnostic tests, and increased funding for R&D by both public and private sectors present significant opportunities. Additionally, AI and big data analytics are offering potential avenues for innovation, driving forward surveillance methodologies. However, the market faces challenges, including high costs associated with novel diagnostic technologies and limited expertise in low-resource settings, which represents a barrier to widespread implementation. Furthermore, discrepancies in data due to varying standards and surveillance capacities across nations complicate global efforts. For business growth, innovation should focus on enhancing cost-effectiveness and accessibility of rapid diagnostics, exploiting AI for predictive modeling, and expanding point-of-care testing. Continuous collaboration with international health organizations can also provide strategic advantages. The market's nature is dynamic, reflecting an urgent demand for solutions, pushing stakeholders to prioritize adaptation, cross-border collaboration, and the integration of innovative technologies that can outpace rapidly evolving microbial threats.

KEY MARKET STATISTICS
Base Year [2023] USD 5.60 billion
Estimated Year [2024] USD 5.96 billion
Forecast Year [2030] USD 8.71 billion
CAGR (%) 6.49%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antimicrobial Resistance Surveillance Market

The Antimicrobial Resistance Surveillance Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of infections caused by pathogens
    • Rising government initiatives to improve the quality of diagnostics and point-of-care diagnosis
  • Market Restraints
    • High cost associated with antimicrobial resistance surveillance
  • Market Opportunities
    • Growing demand for advanced diagnostic solutions to manage Antimicrobial Resistance (AMR) infections
    • Increasing regulatory approvals of diagnostics products worldwide
  • Market Challenges
    • Lack of standardized methods and guidelines for AMR surveillance

Porter's Five Forces: A Strategic Tool for Navigating the Antimicrobial Resistance Surveillance Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antimicrobial Resistance Surveillance Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antimicrobial Resistance Surveillance Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antimicrobial Resistance Surveillance Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antimicrobial Resistance Surveillance Market

A detailed market share analysis in the Antimicrobial Resistance Surveillance Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antimicrobial Resistance Surveillance Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antimicrobial Resistance Surveillance Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antimicrobial Resistance Surveillance Market

A strategic analysis of the Antimicrobial Resistance Surveillance Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antimicrobial Resistance Surveillance Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Inc., acquired by bioMerieux SA, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMerieux SA, Bruker Corporation, Cepheid by Danaher Corporation, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Hologic, Inc., Illumina, Inc., Johnson & Johnson Services Inc., Liofilchem S.r.l., Luminex Corporation by DiaSorin S.p.A., Merck & Co., Inc., Novo Holdings A/S, OpGen, Inc., Pfizer Inc., QIAGEN GmbH, Sanofi S.A., Thermo Fisher Scientific Inc., Venatorx Pharmaceuticals, Inc., Viatris Inc., Vivli Inc., and Wolters Kluwer N.V..

Market Segmentation & Coverage

This research report categorizes the Antimicrobial Resistance Surveillance Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Diagnostic Kits, Diagnostic Systems, Services, and Software.
  • Based on End-User, market is studied across Hospitals and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of infections caused by pathogens
      • 5.1.1.2. Rising government initiatives to improve the quality of diagnostics and point-of-care diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with antimicrobial resistance surveillance
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing demand for advanced diagnostic solutions to manage Antimicrobial Resistance (AMR) infections
      • 5.1.3.2. Increasing regulatory approvals of diagnostics products worldwide
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardized methods and guidelines for AMR surveillance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: Significant role of diagnostic kits in offering rapid detection of specific resistance markers at relatively lower costs
    • 5.2.2. End-User: Increasing incidence of hospital-acquired infections developed necessities for next generation antimicrobial resistance (AMR) surveillance
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antimicrobial Resistance Surveillance Market, by Component

  • 6.1. Introduction
  • 6.2. Diagnostic Kits
  • 6.3. Diagnostic Systems
  • 6.4. Services
  • 6.5. Software

7. Antimicrobial Resistance Surveillance Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Research & Academic Institutes

8. Americas Antimicrobial Resistance Surveillance Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Antimicrobial Resistance Surveillance Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Antimicrobial Resistance Surveillance Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. AI-Driven AMRx Tool Advanced Antimicrobial Resistance Diagnosis and Treatment, Enhancing Accuracy and Patient Outcomes
    • 11.3.2. Visby Medical Secures USD 1.8 Million to Advance Portable Gonorrhea Test with Antibiotic Resistance Screening
    • 11.3.3. Novo Holdings Strengthens Fight Against Drug-Resistant Infections by Acquiring Paratek Pharmaceuticals
    • 11.3.4. AMR Action Fund Expands Investment Efforts to Tackle Antibiotic Resistance
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Accelerate Diagnostics, Inc.
  • 3. acquired by bioMerieux SA
  • 4. Agilent Technologies, Inc.
  • 5. Becton, Dickinson and Company
  • 6. bioMerieux SA
  • 7. Bruker Corporation
  • 8. Cepheid by Danaher Corporation
  • 9. F. Hoffmann-La Roche Ltd
  • 10. GlaxoSmithKline PLC
  • 11. Hologic, Inc.
  • 12. Illumina, Inc.
  • 13. Johnson & Johnson Services Inc.
  • 14. Liofilchem S.r.l.
  • 15. Luminex Corporation by DiaSorin S.p.A.
  • 16. Merck & Co., Inc.
  • 17. Novo Holdings A/S
  • 18. OpGen, Inc.
  • 19. Pfizer Inc.
  • 20. QIAGEN GmbH
  • 21. Sanofi S.A.
  • 22. Thermo Fisher Scientific Inc.
  • 23. Venatorx Pharmaceuticals, Inc.
  • 24. Viatris Inc.
  • 25. Vivli Inc.
  • 26. Wolters Kluwer N.V.

LIST OF FIGURES

  • FIGURE 1. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, FPNV POSITIONING MATRIX, 2023